Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Yagaanbuyant, Dagvadorj

Loading...
Thumbnail Image
Товч нэр
Yagaanbuyant, Dagvadorj
Бүтэн нэр
Yagaanbuyant Dagvadorj
Латин нэр
Yagaanbuyant Dagvadorj
Албан тушаал
Судлаач
Харьяалал

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Treatment of Chronic HCV Infection with Direct Acting Antivirals
    (Mongolian National University of Medical Sciences, 2021-09-21)
    Bekhbold Dashtseren
    ;
    Zulkhuu Genden
    ;
    Odgerel Oidovsambuu
    ;
    Anir Enkhbat
    ;
    Ganbolor Jargalsaikhan
    Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Hepatitis C Associated B-Cell Non-Hodgkin Lymphoma: Impact of Combination Direct-Acting Antivirals and Chemotherapy
    (Mongolian National University of Medical Sciences, 2021-12-31)
    Myagmarjav Budeebazar
    ;
    Delgerbat Boldbaatar
    ;
    Khishigjargal Batsukh
    ;
    Erdenetsogt Dungubat
    ;
    Dagvadorj Yagaanbuyant
    Objectives: Direct-acting antiviral agents (DAAs) have successfully eradicated chronic hepatitis C virus (HCV) infection. Since chronic HCV is known to have an increased risk of developing B cell non-Hodgkin lymphoma (B-NHL), successful HCV treatment may have virologic, hepatic, and oncologic benefits for B-NHL. Therefore, this study aimed to determine the efficacy of DAAs combined with chemotherapy in B-NHL patients with chronic HCV in Mongolia. Methods: This case-control study included newly diagnosed B-NHL patients with chronic HCV who received DAAs before chemotherapy (with DAAs group). The other is comprised of controls who have been treated by chemotherapy without DAAs. Patients who received courses of DAAs were monitored by the virological and hepatic responses. Results: Eleven patients received DAAs and none of them developed chemotherapy-associated hepatitis flare. Of the DAAs group, during DAAs treatment, 90.9% were clinically stable. In all cases of DAAs in combination with chemotherapy, the Sustained Viral Response (SVR)12 and 24 were 100%. However, 47.4% of those who received DAAs after chemotherapy developed hepatitis flare during chemotherapy. Patients with hepatitis flare had higher serum level of ALT before chemotherapy (15.7 U/L vs. 40.2 U/L; p = 0.014) than those without. Conclusion: DAAs administration results in a significant clinical benefit to B-NHL patients with chronic HCV.